Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed. Patients with hormone ...
Dato-DXd significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. The study showed a 37% reduction in disease progression or ...
Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast ...
A retrospective study sought to confirm real-world outcomes of patients with HER2+ breast cancer treated with trastuzumab deruxtecan.
Adults with locally advanced/metastatic NSCLC received 0.27-10 mg/kg Dato-DXd once every 3 weeks during escalation or 4, 6, or 8 mg/kg Dato-DXd once every 3 weeks during expansion. Primary end points ...
New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results